Circulating tumor cells as a prognostic factor in patients with small cell lung cancer

Igawa,Satoshi; Gohda,Keigo; Fukui,Tomoya; Ryuge,Shinichiro; Otani,Sakiko; Masago,Akinori; Sato,Jun; Murakami,Katsuhiro; Maki,Sachiyo; Katono,Ken; Takakura,Akira; Sasaki,Jiichiro; Satoh,Yukitoshi; Masuda,Noriyuki

doi:10.3892/ol.2014.1940

Circulating tumor cells as a prognostic factor in patients with small cell lung cancer

Authors:
- Satoshi Igawa
- Keigo Gohda
- Tomoya Fukui
- Shinichiro Ryuge
- Sakiko Otani
- Akinori Masago
- Jun Sato
- Katsuhiro Murakami
- Sachiyo Maki
- Ken Katono
- Akira Takakura
- Jiichiro Sasaki
- Yukitoshi Satoh
- Noriyuki Masuda
View Affiliations

Affiliations: Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa 252‑0374, Japan, Central Research Laboratories, Sysmex Corporation, Kobe, Hyōgo 651‑2271, Japan, Department of Thoracic Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252‑0374, Japan
Published online on: March 5, 2014 https://doi.org/10.3892/ol.2014.1940
Pages: 1469-1473

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The detection of circulating tumor cells (CTCs) in peripheral blood is currently an important field of study. Detection of CTCs by the OBP‑401 assay (TelomeScan®) has previously been reported to be useful in the diagnosis, prognosis and evaluation of therapeutic efficacy in breast and gastric cancer. The aim of the present study was to evaluate the OBP‑401 assay as a novel method of detecting CTCs of small cell lung cancer (SCLC) patients and to evaluate whether CTC count is associated with prognosis. Prospectively, 30 consecutively diagnosed SCLC patients who had commenced chemotherapy or chemoradiotherapy were enrolled as subjects of the current study. Peripheral blood specimens were collected from the SCLC patients prior to and following the initiation of treatment and the viable CTCs were detected in the specimens following incubation with a telomerase‑specific, replication‑selective, oncolytic adenoviral agent, which was carrying the green fluorescent protein gene. CTCs were detected in 29 patients (96%). The group of 21 patients with a CTC count of <2 cells/7.5 ml prior to treatment (baseline) had a significantly longer median survival time than the group of eight patients with a CTC count of ≥2 cells/7.5 ml prior to treatment (14.8 and 3.9 months, respectively; P=0.007). The results of a multivariate analysis showed that the baseline CTC count was an independent prognostic factor for survival time (hazard ratio, 3.91; P=0.026). Among the patients that achieved a partial response to treatment, patients who had a CTC count of <2 cells/7.5 ml following two cycles of chemotherapy tended to have a longer median progression‑free survival compared with patients who had a CTC count of ≥2 cell/7.5 ml (8.3 and 3.8 months, respectively; P=0.07). Therefore, CTCs may be detected via OBP‑401 assay in SCLC patients and the CTC count prior to treatment appears to be a strong prognostic factor.

View Figures

View References

1	Jackman DM and Johnson BE: Small-cell lung cancer. Lancet. 366:1385–1396. 2005. View Article : Google Scholar : PubMed/NCBI
2	Govindan R, Page N, Morgensztern D, et al: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 24:4539–4544. 2006.PubMed/NCBI
3	Turrisi AT III, Kim K, Blum R, et al: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 340:265–271. 1999. View Article : Google Scholar
4	Takada M, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 20:3054–3060. 2002. View Article : Google Scholar
5	Alix-Panabières C, Riethdorf S and Pantel K: Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res. 14:5013–5021. 2008.
6	Tanaka F, Yoneda K, Kondo N, et al: Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res. 15:6980–6986. 2009. View Article : Google Scholar : PubMed/NCBI
7	Rolle A, Günzel R, Pachmann U, Willen B, Höffken K and Pachmann K: Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC(R) is a predictor for relapse: A preliminary report. World J Surg Oncol. 3:182005. View Article : Google Scholar
8	Taki M, Kagawa S, Nishizaki M, et al: Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 (‘Telomelysin-RGD’). Oncogene. 24:3130–3140. 2005.PubMed/NCBI
9	Fujiwara T, Kagawa S, Kishimoto H, et al: Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy. Int J Cancer. 119:432–440. 2006. View Article : Google Scholar
10	Greider CW and Blackburn EH: Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell. 43:405–413. 1985. View Article : Google Scholar : PubMed/NCBI
11	Collins K and Mitchell JR: Telomerase in the human organism. Oncogene. 21:564–579. 2002. View Article : Google Scholar : PubMed/NCBI
12	Kim NW, Piatyszek MA, Prowse KR, et al: Specific association of human telomerase activity with immortal cells and cancer. Science. 266:2011–2015. 1994. View Article : Google Scholar
13	Shay JW and Wright WE: Telomerase activity in human cancer. Curr Opin Oncol. 8:66–71. 1996. View Article : Google Scholar
14	Nakayama J, Tahara H, Tahara E, et al: Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet. 18:65–68. 1998. View Article : Google Scholar
15	Kim SJ, Masago A, Tamaki Y, et al: A novel approach using telomerase-specific replication-selective adenovirus for detection of circulating tumor cells in breast cancer patients. Breast Cancer Res Treat. 128:765–773. 2011. View Article : Google Scholar
16	Ito H, Inoue H, Sando N, et al: Prognostic impact of detecting viable circulating tumour cells in gastric cancer patients using a telomerase-specific viral agent: a prospective study. BMC Cancer. 12:3462012. View Article : Google Scholar
17	Yabusaki M, Sato J, Kohyama A, et al: Detection and evaluation of circulating tumor cells in digestive system cancers using telomerase-specific adenovirus. In: Proceeding of 71st annual meeting of the Japan Cancer Association abst; 3395. 2012
18	Takakura M, Kyo S, Nakamura M, et al: Circulating tumour cells detected by a novel adenovirus-mediated system may be a potent therapeutic marker in gynaecological cancers. Br J Cancer. 107:448–454. 2012. View Article : Google Scholar
19	Hiltermann TJ, Pore MM, van den Berg A, et al: Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann Oncol. 23:2937–2942. 2012. View Article : Google Scholar : PubMed/NCBI
20	Naito T, Tanaka F, Ono A, et al: Prognostic impact of circulating tumor cells in patients with small cell lung cancer. J Thorac Oncol. 7:512–519. 2012. View Article : Google Scholar : PubMed/NCBI
21	Hou JM, Krebs MG, Lancashire L, et al: Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol. 30:525–532. 2012. View Article : Google Scholar : PubMed/NCBI
22	Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002. View Article : Google Scholar : PubMed/NCBI
23	Yilmaz M and Christofori G: EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 28:15–33. 2009. View Article : Google Scholar : PubMed/NCBI
24	Sieuwerts AM, Kraan J, Bolt J, et al: Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst. 101:61–66. 2009. View Article : Google Scholar : PubMed/NCBI
25	Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R and Kasimir-Bauer S: Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 11:R462009. View Article : Google Scholar
26	Bonnomet A, Brysse A, Tachsidis A, et al: Epithelial-to-mesenchymal transitions and circulating tumor cells. J Mammary Gland Biol Neoplasia. 15:261–273. 2010. View Article : Google Scholar : PubMed/NCBI
27	Lu J, Fan T, Zhao Q, et al: Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients. Int J Cancer. 126:669–683. 2010. View Article : Google Scholar : PubMed/NCBI